Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2018, Article ID 5217301, 5 pages
https://doi.org/10.1155/2018/5217301
Case Report

Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency

Department of Respiratory Medicine, Okinawa Prefectural Nanbu Medical Center & Children’s Medical Center, Okinawa, Japan

Correspondence should be addressed to Koken Ameku; pj.evil@ekocqema

Received 28 September 2017; Revised 2 December 2017; Accepted 4 January 2018; Published 23 January 2018

Academic Editor: Simon Davidson

Copyright © 2018 Koken Ameku and Mariko Higa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Brouwer, N. J. Veeger, H. C. Kluin-Nelemans, and J. van der Meer, “The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes,” Annals of Internal Medicine, vol. 145, no. 11, pp. 807–815, 2006. View at Publisher · View at Google Scholar
  2. N. Hamasaki, H. Kuma, and H. Tsuda, “Activated protein C anticoagulant system dysfunction and thrombophilia in Asia,” Annals of Laboratory Medicine, vol. 33, no. 1, pp. 8–13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. K. ten Kate and J. van der Meer, “Protein S deficiency: a clinical perspective,” Haemophilia, vol. 14, no. 6, pp. 1222–1228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. E. Burnett, C. E. Mahan, S. R. Vazquez, L. B. Oertel, D. A. Garcia, and J. Ansell, “Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment,” Journal of Thrombosis and Thrombolysis, vol. 41, no. 1, pp. 206–232, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Lipe and D. L. Ornstein, “Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin,” Circulation, vol. 124, no. 14, pp. e365–e368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Skelley, C. W. White, and A. R. Thomason, “The use of direct oral anticoagulants in inherited thrombophilia,” Journal of Thrombosis and Thrombolysis, vol. 43, no. 1, pp. 24–30, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. EINSTEIN Investigators, R. Bauersachs, S. D. Berkowitz, and B. Brenner, “Oral rivaroxaban for symptomatic venous thromboembolism,” New England Journal of Medicine, vol. 363, no. 26, pp. 2499–2510, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Undas and T. Góralczyk, “Direct oral anticoagulants in patients with thrombophilia: challenges in diagnostic evaluation and treatment,” Advances in Clinical and Experimental Medicine, vol. 25, no. 6, pp. 1321–1330, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Martinelli, P. Bucciarelli, A. Artoni et al., “Anticoagulant treatment with rivaroxaban in severe protein S deficiency,” Pediatrics, vol. 132, no. 5, pp. e1435–e1439, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Z. Haran, I. Lichman, A. Berebbi, E. Weinmann, and N. Rosenberg, “Unbalanced protein S deficiency due to warfarin treatment as a possible cause for thrombosis,” British Journal of Haematology, vol. 139, no. 2, pp. 310-311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. O. R. Odegaard, A. K. Lindahl, K. Try, G. Kvalheim, and J. Hjalmar Sørbø, “Recurrent venous thrombosis during warfarin treatment related to acquired protein S deficiency,” Thrombosis Research, vol. 66, no. 6, pp. 729–734, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Sallah, J. M. Abdallah, and G. A. Gagnon, “Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency,” Haemostasis, vol. 28, no. 1, pp. 25–30, 1998. View at Google Scholar
  13. F. Andreotti, B. Rocca, S. Husted et al., “Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis,” European Heart Journal, vol. 36, no. 46, pp. 3238–3249, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Karamichalakis, S. Georgopoulos, K. Vlachos et al., “Efficacy and safety of novel anticoagulants in the elderly,” Journal of Geriatric Cardiology, vol. 13, no. 8, pp. 718–723, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Miyata, K. Maruyama, F. Banno, and R. Neki, “Thrombophilia in East Asian countries: are there any genetic differences in these countries?” Thrombosis Journal, vol. 14, p. 25, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. P. García de Frutos, P. Fuentes-Prior, B. Hurtado, and N. Sala, “Molecular basis of protein S deficiency,” Thrombosis and Haemostasis, vol. 98, no. 3, pp. 543–556, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Maruyama, M. Akiyama, K. Kokame, A. Sekiya, E. Morishita, and T. Miyata, “ELISA-based detection system for protein S K196E Mutation, a genetic risk factor for venous thromboembolism,” PLoS One, vol. 10, no. 7, Article ID e0133196, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. A. G. G. Turpie, D. Purdham, and A. Ciaccia, “Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment,” Therapeutic Advances in Cardiovascular Disease, vol. 11, no. 9, pp. 243–256, 2017. View at Publisher · View at Google Scholar
  19. EINSTEIN–PE Investigators, H. R. Büller, M. H. Prins, and A. W. Lensin, “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism,” New England Journal of Medicine, vol. 366, no. 14, pp. 1287–1297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. H. Prins, A. W. Lensing, R. Bauersachs et al., “Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies,” Thrombosis Journal, vol. 11, no. 1, p. 21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. R. M. Bauersachs, A. W. Lensing, M. H. Prins et al., “Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment,” Thrombosis Journal, vol. 12, p. 25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Geldhof, C. Vandenbriele, P. Verhamme, and T. Vanassche, “Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants,” Thrombosis Journal, vol. 12, p. 21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka, “Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban,” Clinical Pharmacokinetics, vol. 53, no. 1, pp. 1–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Yamada, A. Hirayama, H. Maeda et al., “Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program,” Thrombosis Journal, vol. 13, p. 2, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. J. I. Weitz, A. W. A. Lensing, M. H. Prins et al., “Rivaroxaban or aspirin for extended treatment of venous thromboembolism,” New England Journal of Medicine, vol. 376, no. 13, pp. 1211–1222, 2017. View at Publisher · View at Google Scholar · View at Scopus